2. Qualitative and Quantitative Composition
Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may
Download 2. Qualitative and Quantitative Composition
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
XHANCE™ Full Prescribing Information
www.xhance.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE XHANCE™ nasal spray is indicated for the treatment of nasal polyps in patients 18 years of age or older.
RI N A E ARIA UPD W ATE At-A-Glance Pocket …
aaia.caBASEDONTHEALLERGICRHINITISANDITSIMPACTONASTHMA WORKSHOPREPORT IncollaborationwiththeWorldHealthOrganisation, GA 2LEN,andAllerGen ARIA At-A-Glance Pocket Reference 2007
Pharmacy and Therapeutics Committee-approved …
ww4.mgh.orgPharmacy and Therapeutics Committee-approved Therapeutic Interchanges Therapeutic Interchange Revision Date Alpha Blockers …
INTRANASAL CORTICOSTEROIDS - RxFiles
www.rxfiles.caNov 01, 2003 · INTRANASAL CORTICOSTEROIDS a Supplement to the OTC Products Chart January, 2004 The RxFiles Academic Detailing Program c/o Saskatoon City Hospital, 701 Queen Street
2015.06.16 Alanase DS - Medsafe Home Page
www.medsafe.govt.nzPage 3 of 5 Warnings and Precautions Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged
APPENDIX C MAXIMUM ALLOWABLE COST (MAC) …
formulary.drugplan.health.gov.sk.caAPPENDIX C. MAXIMUM ALLOWABLE COST (MAC) POLICY. For many common medical conditions, drug manufacturers market a wide variety of prescription drugs that often vary in price but achieve the same medical effect.
ABHB Prescribing Guideline When to Issue a Steroid ...
www.wales.nhs.ukprescribers should refer to individual summary of product characteristics for full prescrbing information status: approved issue date: april 2008 updated may 2012